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REKOMBINAN PIRUVAT FOSFAT DIKINASE (rPPDK): PEMBANGUNAN 
UJIAN DIPSTIK PANTAS ANTIBODI DAN ANTIGEN BAGI AMEBIASIS 
DAN  PENGENALPASTIAN POTENSI SEBATIAN ANTI-AMEBIK 
 
ABSTRAK 
Amebiasis, sejenis penyakit protozoa enterik yang disebabkan oleh 
Entamoeba histolytica, merupakan satu masalah kesihatan awam di kebanyakan 
negara membangun. Amebiasis intestinal boleh menyebabkan simptom seperti kolitis 
dan disenteri; manakala amebiasis ekstraintestinal kebiasaannya menyebabkan abses 
hepar jangkitan ameba (ALA). Asai pengesanan antigen komersil yang tersedia 
untuk jangkitan intestinal menunjukkan sensitiviti dan spesifisiti yang berbeza-beza 
manakala ujian yang tersedia untuk ALA menggunakan ekstrak asli antigen parasit 
mempunyai isu spesifisiti. Sebelum ini, piruvat fosfat dikinase (PPDK) telah 
dikenalpasti sebagai penanda untuk mengesan amebiasis ekstraintestinal, maka 
protein dalam bentuk rekombinan (rPPDK) digunakan dalam kajian ini untuk 
membangunkan ujian pantas dipstik antibodi untuk ALA. Pencarian ejen anti-amebik 
sangat penting kerana kesan sampingan metronidazole dan laporan kerintangan 
terhadapnya. PPDK terlibat dalam laluan utama metabolisme tenaga parasit, maka 
PPDK merupakan satu sasaran yang berpotensi untuk pembangunan ejen anti-amebik 
baharu. Oleh itu, kajian ini juga bertujuan untuk menyiasat aktiviti anti-amebik 
secara in vitro daripada sebatian berpotensi dengan menggunakan E. histolytica HM-
1: IMSS. Gen PPDK telah ditempah untuk diklonkan ke dalam vektor pengekspresan 
pET28, ditransformasikan ke dalam E. coli BL21 (DE3), diekspreskan dan 
ditulenkan. Sensitiviti dan spesifisiti diagnostik bagi protein tulen rPPDK dinilai 
melalui pemblotan Western dengan menggunakan sampel serum individu. Untuk 
perbandingan, prosedur di atas juga dijalankan untuk menghasilkan rekombinan 
xxxviii 
 
galaktosa-dan-N-asetil-D-galaktosamina lektin boleh rencat (rGal/GalNAc lektin). 
Ujian pemblotan Western menggunakan serum daripada pesakit ALA, individu yang 
sihat dan penyakit lain yang ditanda dengan menggunakan anti-manusia IgG4-
berkonjugat horseradish menunjukkan nilai sensitiviti (93.3%) dan spesifisiti (100%) 
diagnostik paling tinggi berbanding blot yang menggunakan IgG dan IgG1 sebagai 
antibodi kedua. rPPDK menunjukkan spesifisiti yang lebih baik jika dibandingkan 
dengan  rGal/GalNAc lektin. Ujian pantas dipstik aliran sisi dengan menggunakan 
rPPDK telah dibangunkan dan dinilai untuk serodiagnosis ALA menggunakan 
sampel serum daripada pesakit dan kawalan. Keputusan menunjukkan sensitiviti 
diagnostik sebanyak 96.7% (n=29/30) dan spesifisiti 100% (n=40/40). Dalam 
membangunkan ujian pantas pengesan antigen untuk amebiasis intestinal, antibodi 
poliklonal (PAb) kepada rPPDK, rGal/GalNAc lektin dan antigen perkumuhan-
rembesan E. histolytica (Eh ESA) telah dihasilkan. Pengesanan terbaik E. histolytica 
dalam sampel tinja ditunjukkan apabila anti-rPPDK PAbs digariskan pada dipstik 
dan PAb anti-Eh ESA berkonjugat-emas digunakan sebagai reagen pengesan. 
Prestasi ujian dipstik aliran sisi yang dibangunkan telah dibandingkan dengan ujian 
komersial TechLab E. histolytica II ELISA dan ujian PCR “real-time”, menggunakan 
70 sampel tinja daripada pesakit dan kawalan. Sepuluh sebatian daripada Institut 
Kanser Kebangsaan (NCI) telah dipilih daripada saringan maya sebelum ini yang 
dilakukan ke atas tapak ATP model tiga dimensi PPDK. Dengan menggunakan asai 
enzim, tujuh sebatian menunjukkan aktiviti rencatan, merangkumi NSC349156 dan 
NSC228137 yang menunjukkan nilai MIC masing-masing pada 25 µM dan 50 µM. 
Dengan menggunakan asai penurunan NBT, NSC349156 menunjukkan nilai IC50 
yang terendah (14.04 µM), diikuti oleh NSC228137 (20.7 µM); manakala IC50 bagi 
metronidazole ditentukan pada nilai 6.15 µM. Selepas 24 jam rawatan, NSC228137 
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dan NSC349156 masing-masing menunjukkan 37.61% dan 75.73% rencatan 
pertumbuhan. Kesimpulannya, rPDDK telah berjaya digunakan dalam pembangunan 
ujian pantas antibodi dan juga ujian pengesan antigen masing-masing untuk 
diagnosis ekstraintestinal dan intraintestinal amebiasis. Tambahan pula, dua sebatian 
menunjukkan potensi untuk bertindak sebagai agen anti-amebik. 
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RECOMBINANT PYRUVATE PHOSPHATE DIKINASE (rPPDK): 
DEVELOPMENT OF ANTIBODY AND ANTIGEN RAPID DIPSTICK 
TESTS FOR AMOEBIASIS AND IDENTIFICATION OF POTENTIAL ANTI-
AMOEBIC COMPOUNDS 
 
ABSTRACT 
Amoebiasis, an enteric protozoan disease caused by Entamoeba histolytica, is 
a public health problem in many developing countries. Intestinal amoebiasis may 
produce symptoms such as colitis and dysentery; while extraintestinal amoebiasis 
commonly results in amoebic liver abscess (ALA). The commercial antigen detection 
tests for intestinal infection vary in their sensitivities and specificities; most of them 
use native parasite antigen extract which have specificity issues. Thus this study was 
aimed at improving the laboratory diagnosis of ALA and intestinal amoebiasis. 
Previously, pyruvate phosphate dikinase (PPDK) had been identified as a marker for 
detection of extraintestinal amoebiasis, thus the recombinant form of the protein 
(rPPDK) was used in this study to develop a rapid antibody dipstick test for ALA.  
Search for new anti-amoebic agents is important due to the side-effects of 
metronidazole and reports of resistance against it. PPDK is involved in a key 
pathway in the energy metabolism of the parasite, thus is a promising target for a 
new anti-amoebic agent. Therefore, the present study was also aimed to investigate 
in vitro anti-amoebic activity of potential compounds using E. histolytica HM-1: 
IMSS. The PPDK gene was custom cloned into pET28a(+) expression vector, 
transformed into E. coli BL21 (DE3), expressed and purified. Diagnostic sensitivity 
and specificity of the purified rPPDK protein were evaluated by Western blot using 
individual serum samples. For comparison, the above procedures were also 
performed to produce recombinant galactose-and-N-acetyl-D-galactosamine 
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inhibitable lectin (rGal/GalNAc lectin). Western blots using patients and control 
serum samples probed with anti-human IgG4-HRP showed higher diagnostic 
sensitivity (93.3%) and specificity (100%) as compared to blots using IgG and IgG1 
as secondary antibodies. rPPDK was found to show better specificity when compared 
to rGal/GalNAc lectin. A rapid dipstick test using rPPDK was developed and 
evaluated for ALA serodiagnosis. The results showed 96.7% (n=29/30) diagnostic 
sensitivity and 100% (n=40/40) specificity. For the development of an antigen 
detection rapid test for intestinal amoebiasis, polyclonal antibody (PAb) against 
rPPDK, rGal/GalNAc lectin and E. histolytica excretory-secretory antigens (Eh ESA) 
were produced. The best detection of E. histolytica in stool samples was shown when 
anti-rPPDK PAb was lined on the dipstick and gold conjugated anti-Eh ESA PAb 
was used as the detector reagent. Performance of the developed dipstick test was 
compared with commercial TechLab E. histolytica II ELISA and real-time PCR, 
using 70 stool samples from patients and controls. Ten compounds from the National 
Cancer Institute (NCI) were selected from a previous virtual screening performed 
against ATP site of a three-dimensional PPDK model. Using an enzymatic assay, 
seven of the compounds showed inhibitory activities, they include NSC349156 and 
NSC228137 with MIC values of 25 µM and 50 µM respectively. Using NBT 
reduction assay, NSC349156 showed the lowest IC50 (14.04 µM), followed by 
NSC228137 (20.7 µM); while IC50 of metronidazole was 6.15 µM. After 24 hours of 
treatment, NSC228137 and NSC349156 exhibited 37.61% and 75.73% growth 
inhibition, respectively. In conclusion, rPPDK was successfully used in this study for 
development of rapid antibody and antigen detection tests for diagnosis of 
extraintestinal and intestinal amoebiasis respectively. In addition, two compounds 
showed potential to serve as anti-amoebic agents.  
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CHAPTER ONE 
INTRODUCTION 
 
1.1 Overview of amoebiasis 
 
Neglected tropical diseases (NTD) are a diverse group of chronic and disabling 
diseases that are found in very poor areas and affect more than one billion people 
globally (Hotez et al., 2007). Many of the world’s NTDs occur in poor populations in 
twenty countries (Group of 20), which are mostly tropical and subtropical such as 
Brazil, Mexico, Indonesia, India, Bangladesh and China (Hotez et al., 2013).  The 
major parasitic diseases of the NTDs include amoebiasis, malaria, leishmaniasis, 
Chagas’s disease, schistosomiasis, lymphatic filariasis, strongyloidiasis, ascariasis, 
onchocerciasis and trichuriasis. Amoebiasis (caused by Entamoeba histolytica) is 
estimated to affect 50 million people worldwide and causes up to 100 000 deaths 
annually.  In terms of mortality due to protozoan parasites, it ranks in second place 
after malaria (Stanley, 2003; Fotedar et al., 2007a). Of these, 90% are asymtomatic 
carrier, whereas the other 10% of infected individuals show clinical symptoms such 
as colitis, dysentery and extraintestinal amoebiasis (Fotedar et al., 2007a). The most 
common clinical manifestation of extraintestinal is amoebic liver abscess (ALA) and 
a delay in diagnosis and treatment may cause fatality (Zlobl, 2001). The disease is 
usually found in areas with poor sanitary conditions and low socioeconomic status. 
The only reservoir is humans, and infection occurs via food, water or hands 
contaminated with cyst-containing faeces. Human to human transmission has also 
been reported, that is, through oral-genital or oral-anal contact, especially among 
homosexual men (Hung et al., 2008), as well as travellers from endemic areas, and 
those with poor personal hygiene (Rivero et al., 2008). 
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The epidemiology of amoebiasis varies between countries and continents due 
to ecological, social-culture and economic factors (Blessmann et al., 2002a; 
Haghighi et al., 2003; Ali et al., 2008; Ximanez et al., 2009). For example, Fotedar 
et al, (2007a) reported the prevalence of Entamoeba infection is as high as 50% in 
endemic areas of Central and South America, Africa and Asia. Hung et al. (2008) 
and Watanabe et al. (2011) reported an increasing risk of amoebiasis in Taiwan, 
Japan and South Korea, especially among homosexual men who practice oral-anal 
sex. In Southeast Asia, this disease is commonly found in the following 
communities-aborigines, those living in poor sanitary conditions, rural and urban 
populations with low socioeconomic status, and immigrants from amoebiasis 
endemic areas (Mahmud et al., 2013).  
Many diagnostic tests have been developed for the accurate detection of E. 
histolytica in clinical samples, such as polymerase chain reaction (PCR) and enzyme-
linked immunosorbent assay (ELISA) (Packers, 2002). However, some ELISAs do 
not show good sensitivity and specificity when used in low to medium endemic 
areas, especially in developing and underdeveloped countries (Zengzhu et al., 1999; 
Fotedar et al., 2007a; Zeehaida et al., 2008). Thus, there is an urgent need to improve 
the diagnostic techniques for the detection of intestinal and extraintestinal 
amoebiasis. Despite the prevalence of amoebiasis, there is still no available vaccine 
to prevent this deadly disease (Stanley, 2006). However, there have been progresses 
in research on potential vaccine candidates, the immunization route, and 
understanding of the protective immune responses against amoebiasis (Parija, 2011).   
Nevertheless, amoebiasis is still a big challenge to public health in many 
regions, especially in the ‘bottom billion’ countries (Stanley, 2003). According to 
WHO (1997), the eradication of amoebiasis is essentially based on the improvement 
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of the quality of living conditions and education in the countries where the disease is 
prevalent (Salles et al., 2003). Therefore, continuous improvement of the health 
programme, as well as monitoring and mapping the prevalence of amoebiasis is 
needed to achieve better prevention, diagnosis and treatment of the disease. 
 
1.2 Entamoeba histolytica  
1.2.1 Taxonomy 
Traditionally, Entamoeba spp. have been placed in the phylum Sarcodina due to the 
presence of pseudopodia. However, based on molecular trees, Cavalier-Smith (2004) 
has classified Entamoeba spp. in the phylum of Amoebozoa, class of Archamoebea 
and are closely related to the slime mold. Humans are colonized by several species of 
Entamoeba, however most of them do not cause disease. E. histolytica is a well-
known human pathogenic species that causes intestinal and extraintestinal 
amoebiasis. According to Pritt and Clark (2008), two non-pathogenic species of 
Entamoeba i.e. E. dispar and E. moshkovskii which show identical morphology but 
are genetically distinct, are responsible for most of the 
asymptomatic Entamoeba infections in humans. Therefore, the term amoebiasis is 
generally applied only to the disease caused by E. histolytica (WHO, 1997).  
 
1.2.2 The biology of Entamoeba histolytica 
E. histolytica is a unicellular eukaryotic organism that can be detected under the 
microscope in two different stages, i.e. cysts and trophozoites. Figure 1.1(a) shows 
the trophozoite ranges in size from 10-60 µM and is pleomorphic in shape. When 
isolated from the host, the cytoplasm of the trophozoite often shows ingested red 
blood cells (RBCs). It moves with the help of a single uroid (pseudopodium) and 
4 
 
mostly shows a single nucleus. Rough endoplasmic reticulum and Golgi bodies are 
not visible. Ribosomes are arranged in helices in the cytoplasm and a microtubular 
cytoskeletal network is not visible. The trophozoite is actively multiplying and 
highly motile in a human host. The pseudopods produced by an actively moving 
trophozoite are broad and finger-like, and the parasite generally moves in one 
direction at a time. Entamoeba trophozoites contain proteasomes in their cytoplasm, 
and these play an important role in cell differentiation and replication (Martínez-
Palomo, 1982; Makioka et al., 2002).  
The shape of the cyst is round with diameter of 10-20 µM [Figure 1.1(b)]. It 
is an infective dormant stage and resistant to environmental stresses. A cyst initially 
has a single nucleus, while a mature cyst contains four nuclei. Each nucleus consists 
of a central karyosome surrounded by peripheral chromatin. Rod-like chromatoid 
bodies made of the assemblies of glycogen and ribosome may also be present, but 
they are more common in immature cysts.  
Many of the enzyme metabolites which are produced by E. histolytica are 
believed to be originated from prokaryote, probably obtained via lateral gene transfer 
from bacteria (Yang et al., 1994; Clark & Roger, 1995; Rosenthal et al., 1997). The 
cyst cytoplasm has vacuoles with glycogen deposits which can be visible by 
permanent stains (Lohia, 2013). According to McLaughlin and Aley (1985), E. 
histolytica lacks gluthatione and thus is unable to perform de novo purine synthesis, 
and this differentiates it from higher eukaryotes. In addition, the organization of E. 
histolytica gene is also different from other eukaryotes (Tannich et al., 1992; Clark & 
Diamond, 1993). The ribosomal DNA (rDNA) episome map has been completely 
sequenced. The size of the circular DNA of E. histolytica is approximately 24.5 kb  
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Figure 1.1 Morphological descriptions of E. histolytica or E. dispar (a) 
trophozoites and (b) cyst (CDC, 2010). 
a) 
b) 
Ingested RBC 
Karyosome 
Pseudopodia 
Trophozoite of E. histolytica or E. 
dispar stained with heamatoxylin.  
Trophozoite has a single nucleus, 
which has centrally placed 
karyosome and uniformly 
distributed peripheral chromatin.  
Nucleus  
Cytoplasm  
Cyst of E. histolytica or E. dispar 
stained with haematoxylin.  
Chromatoidal 
bodies 
Karyosome 
Nucleus 
Mature E. histolytica or E. dispar 
cyst has four nuclei that 
characteristically have centrally 
located karyosome and fine, 
uniformly distributed peripheral 
chromatin. 
Trophozoite 
Cyst 
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and has been shown to be useful in genotyping of enteric amoebae (Bhattacharya et 
al., 1989). 
E. histolytica, like Giardia lamblia is a type I amitochondriate protist, lacking 
both mitochondria and hydrogenosomes (Martin & Muller, 1998) [type II 
amitochondriate contains only hydrogenosomes]. These organisms lack features of 
aerobic eukaryotic metabolism, including the tricarboxylic acid (TCA) cycle and 
oxidative phosphorylation, and energy generation is primarily by substrate-level 
phosphorylation. In E. histolytica, an extended glycolysis pathway is present, in 
which pyruvate is converted to acetyl-coA by an enzyme called pyruvate ferredoxin 
oxidoreductase (PFOR). Subsequently, acetyl-coA can either be converted to acetate 
with ATP generation, or reduced to ethanol with regeneration of NAD (oxidized 
nicotinamide adenine dinucleotide) (Muller, 1998; Reeves, 1984; Haanstra et al., 
2008). 
 
1.2.3 Life cycle  
The E. histolytica life cycle is shown in Figure 1.2. The infection usually begins by 
ingestion of water or food that has been contaminated by E. histolytica cysts. Once 
the cysts reach the distal ileum, the intestinal secretions activate excytation whereby 
the quadrinucleated cysts develop into four motile trophozoites. Subsequently the 
amoebas undergo a round of nuclear division, followed by three rounds of cell 
division by binary fission that produces eight trophozoites. The trophozoites mostly 
colonize the cecal and sigmoidorectal regions of the large intestine, where they 
undergo another few rounds of divisions. The motile trophozoites adhere to and 
invade the cells of the gastrointestinal epithelium.     
 
7 
 
The invasion of colon is initiated by the parasite adherence and lysis of the 
colon epithelium, and this process is mediated by galactose and N-acetyl-D-
galactosamine (Gal/GalNAc)-specific lectin of the trophozoite (Petri, 2002). Once 
the intestinal ephitalieum is invaded, trophozoites may spread to other parts of body, 
and most frequently end up in the liver, causing ALA. The factors that control 
invasion of the epithelial cells are most probably due to quorum sensing signalled by 
the amoebic Gal/GalNAc lectin, host innate and acquired immune responses and the 
interaction of the parasite with the intestinal bacterial flora (Tanyuksel & Petri, 
2003). Some of the trophozoites may undergo encystment, in which the nucleus goes 
through two division processes to produce a quadrinucleate cyst, and may be 
excreted from the body through the stool. The factor responsible for the induction of 
encystation is unknown. López-Romero and Villagómez-Castro (1993), and 
Eichinger (1997) described that encystation is initiated when trophozoites round up 
into spherical forms, followed by formation of chromatoidal bodies in the cytoplasm. 
These bodies are ribosomal aggregates and when stained appear as elongated 
structures with rounded ends. Studies on E. invadens suggested that the process of 
encystation may be triggered by ligation of a surface galactose binding lectin on the 
surface of the protozoa (Eichinger, 2001; Stanley, 2003). Coppi et al, (2002) 
postulated that trophozoites aggregation in the mucin layer may also be a trigger for 
the encystation.  
The cyst wall is smooth and refractile, and is made up of chitin. The 
maturation of cyst involves two rounds of nuclear replication, without any cell 
division. The cyst nucleus is morphologically similar to that of the trophozoite, 
however it becomes smaller with each division. Cysts can remain alive outside the  
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Figure 1.2 Life cycle of E. histolytica (CDC, 2010). 
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host for weeks or months, especially in damp conditions, but are rapidly destroyed at 
temperatures below -5°C and over 40°C (Fotedar et al., 2007a).  
The subsequent host may get infected when it ingests food or water 
contaminated with the cyst. Thus far, human and some non-human primates have 
been reported as the only natural hosts of E. histolytica (Stanley, 2003; Rivera et al., 
2010).  Other Entamoeba spp., i.e. E. hartmanii, E. coli and E. polecki, can be 
differentiated from E. histolytica/E. dispar/E. moshkovskii by microscopy (Tanyuksel 
& Petri, 2003; Fotedar et al., 2007a). A detailed description of the microscopic 
morphologies of the various Entamoeba spp. are described in section 1.8.1(a) [Figure 
1.5 and Table 1.1] on pages 31-33. 
 
1.3 Mode of transmission   
In general, amoebiasis is transmitted via fecal-oral route, through the cysts ingestion 
from contaminated water or food (Tanyuksel & Petri, 2003). However, the parasite 
can also be transmitted among homosexual and institutionalized persons via oral–
genital or oral–anal contact (Gatti et al., 1995; Shelton, 2004; Moran et al., 2005). 
Amoebiasis also spreads through immigrants who reside in endemic areas and travel 
to other places. Travellers returning from the endemic areas have been reported to 
have a high risk of infection. For instance, 47 of 469 individuals with diarrhoea were 
diagnosed as having amoebiasis after travelling to underdeveloped countries (Jelinek 
et al., 1996). Another report showed that 0.3% of 2 700 German travellers had 
amoebiasis on their return from tropical areas (Weinke et al., 1990). According to the 
Alberta Health and Wellness, Disease Control and Prevention report in year 2003, 
fewer than 80 cases were reported annually from 1995–2004; the infections were 
predominantly detected in individuals who have travelled to an underdeveloped area 
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(http://www.health.alberta.ca/documents/Guidelines-Amoebiasis-2011). Other than 
the above situations, E. histolytica is uncommonly transmitted in industrialized 
countries, and outbreaks are very rare in such places (Knobloch & Mannweiler, 
1983; Salit et al., 2009).   
In addition, there is ambiguity regarding the zoonotic transmission of the 
amoeba from dogs, cats, rats, monkeys and probably pigs (Beaver et al., 1984; 
Krauss et al., 1997). The importance of primates in zoonotic infections was studied 
by Jackson et al. (1990). He investigated whether E. histolytica is a true zoonosis 
using zymodeme analysis. Although E. histolytica is commonly associated with 
animals, there is no report of sporadic transmission between humans and infected 
animals. In 2005, an amoebiasis outbreak was reported to occur among four 
chimpanzees kept in captivity at Sandal Kyarimi Park, Nigeria. Based on the 
laboratory results, cysts and trophozoites of E. histolytica were found in the stools of 
all the chimpanzees during the outbreak. The animals had most likely acquired the 
infection from the human attendants (Mbya & Nwosu, 2005). 
Another study, using a molecular-based method, reported that E. histolytica 
or E. dispar infections were detected among wild rats in Malaysia (Lau et al., 2014). 
Together, these studies showed the potential threats of zoonotic transmission as well 
as the importance of establishing preventive control measures. 
 
1.4 Epidemiological studies on amoebiasis 
Epidemiological studies of amoebiasis have been reported since 1925. Many were 
conducted to investigate the presence of Entamoeba spp. in certain regions such as 
South Africa, Bangladesh, Philippines, Brazil, Egypt and Greece (Haque et al., 1997; 
Haque et al., 1998a; Braga et al., 1998; Rivera et al., 1998; Gathiram & Jackson, 
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1987; Abd-Alla & Ravdin, 2002; Haque & Petri, 2006). However, reliable data were 
only obtained when researchers started to use molecular tools which were able to 
differentiate between species at the DNA level (Clark & Diamond, 1993; Tannich et 
al., 1989; Burch et al., 1991).  This was because microscopic examination is unable 
to distinguish among morphologies of E. histolytica, E. dispar and E. moshkovskii 
(Baron, 1996).  
 
1.4.1 Intestinal amoebiasis 
A study by Nath et al. (2015) using species specific PCR assay found that the 
prevalence rate of E. histolytica at community health care units and hospitals in a 
North East Indian population was 13.7%. Ximenez (2009) reported that the incident 
rate of intestinal amoebiasis in Mexico between 1995-2000 was in range of 1 000 to 
5 000 cases per 100 000 inhabitants. An investigation of Entamoeba infection in 
Sudan, using PCR, reported that the highest rate of infection by E. histolytica, among 
microscopic-positive individuals who attended the University of Medical Sciences 
and Technology (UMST) hospital was 54.1% (Saeed et al., 2011). The study also 
showed that prevalence of co-infection with E. histolytica and E. dispar was 5.1%, 
similar to the co-occurrence rate of E. histolytica and E. dispar in the stool samples 
in Bangladesh as reported by Haque et al. (1998a). Meanwhile, the prevalence of E. 
histolytica infection among preschool children living in Mirpur district of Dhaka, 
Bangladesh was reported to be 4.2%, as determined by E. histolytica II ELISA kit 
(Haque et al. 2006). A survey on the prevalence of intestinal parasites among the 
expatriates and native Emirati people in UAE showed that protozoan infections 
(92.2%) were higher than helminthic infections (7.8%). Among the former, E. 
histolytica/E. dispar (71.8%) and G. lamblia (17.5%) were the most common 
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parasites (ElBakri et al., 2013). In Pakistan the prevalence of E. histolytica/E. dispar, 
as detected using formalin-ether concentration technique (FECT) was reported to be 
8.6% (Tasawar et al., 2013).  
Using PCR assay, Al-Hindi et al. (2005) reported higher prevalence rates of 
E. histolytica (69.6%) than E. dispar (22.8%) among children in Gaza, Palestine. In a 
town near Abidjan, Ivory Coast, PCR analysis showed that the ratio of E. 
histolytica to E. dispar was 1:46 among microscopically positive samples 
(Heckendorn et al., 2002). A study was conducted by Samie et al. (2007) on stool 
samples in South Africa using nested PCR and ELISA. The results showed that E. 
histolytica was detected in 18.8% and 2.1% of samples from public hospitals and 
primary schools respectively.  Meanwhile E. dispar was detected in 25.3 % and 8.5% 
of samples from public hospitals and primary schools respectively. In a clinical 
setting in Sweden, Lebbad et al. (2005) found that 79.7% (165/207) and 4.8% of 
patients’ stools were PCR-positive for E. dispar and E. histolytica respectively. In 
Iran, Mojarad et al. (2010) reported that among 3 825 stool samples, 3.5%, 91.4% 
and 3.5% were PCR-positive for E. histolytica, E. dispar and E. moshkovskii, 
respectively. Another study conducted among prisoners and primary-school children 
in Ethiopia showed that real-time PCR detected E. dispar in 91.5% (195/213) of 
microscopy positive samples (Kebede et al., 2004). In Australia, among microscopy 
positive stool samples at St. Vincent’s Hospital, PCR analysis showed that 70.8% 
and 50% were positive for the non-pathogenic E. dispar and E. moshkovskii 
respectively (Fotedar et al., 2007b). 
Meanwhile in Malaysia, real-time PCR on microscopy positive stool samples 
of Orang Asli (aborigines) showed prevalence rates of 13.2% E. histolytica and 9.9%  
E. dispar  (Lau et al., 2013). On the other hand, a cross sectional study of 500 Orang 
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Asli stool samples using single-round PCR assay showed a high prevalence of E. 
dispar (13.4%), as compared to E. histolytica (3.2%) and E. moshkovskii (1%)  
(Anuar et al., 2012).  In contrast, using nested PCR, Ngui et al. (2012) and Noor 
Azian et al. (2007) reported a high prevalence of 76% and 13.2% E. histolytica 
respectively among the aborigine community. In the year 2004, an amoebiasis 
outbreak was reported at aborigine villages in the Cameron Highlands, and nested 
PCR assays were performed on stool samples collected from individuals with 
diarrhoea. The results showed that E. histolytica and E. dispar were detected in 
13.2% and 5.6% of the stool samples (n=28) respectively (Noor Azian et al., 2006). 
A study among the Malaysian urban population in Kuala Lumpur demonstrated a 
low prevalence (0.4%) of E. histolytica/E. dispar was reported by Jamaiah and 
Rohela (2005). 
According to Hung et al.  (2008), in developed countries amoebiasis is more 
prevalent in older individuals among homosexual men and institutionalized persons. 
Studies in Japan have shown that E. histolytica was more than E. dispar among male 
homosexuals (Takeuchi et al., 1990; Ohnishi et al., 2004). Many researchers from 
Taiwan, Japan and Korea reported an increasing number of HIV-infected 
homosexuals who were diagnosed with invasive amoebiasis. Approximately 80% of 
amoebiasis cases in Japan occurred among homosexuals and most of them were co-
infected with HIV and syphilis (Takeuchi et al., 1987; Ohnishi et al., 2004; Nozaki et 
al., 2006). This finding is in concordance with a study by Hung et al. (2005) in 
Taiwan which showed that HIV-infected individuals were at increased risk for 
invasive amoebiasis, and showed high frequency of increased antibody titers and E. 
histolytica colonization of the intestine.  
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After reviewing all the published reports from 1929 to 1997, Acuna-Soto et 
al. (2000) reported that the male to female ratios for invasive intestinal amoebiasis and 
asymptomatic carriage were 3.2:1 and 1:1, respectively. Most of the asymptomatic 
carriage infections were due to E. dispar. However, according to Rivera et al. (1998) 
who studied 14 communities in the northern Philippines, there was no significant 
difference in gender distributions of E. histolytica. The same observation has also 
been made in other community-based studies (Okafor & Azubike, 1992; Magambo et 
al., 1998; Hamze et al., 2004; Sharma et al., 2004; Tasawar et al., 2010).  
Nevertheless, several hospital-based studies recorded gender preference of E. 
histolytica infection. For example, Ozyurt et al. (2007) reported E. histolytica in 67% 
males as compared to 33% females among patients at a hospital in Turkey. The study 
concurred with Ohnishi and Murata (1997), who found that 26 out of 28 males and 
no females were infected with E. histolytica in the east-southeast area of Tokyo, 
Japan. Conversely, Ozgümüş and Efe (2007) reported that 64% of the attendees of a 
healthcare centre in Turkey who were infected with E. histolytica were females 
(16/25). Gender comparison of E. histolytica infection in Pakistan (hospital-based 
study) showed higher prevalence rate in females (31.5%) than males (19.6%) (Ejaz et 
al., 2011).  
The non-pathogenic species, E. moshkovskii  has also been reported in several 
countries though is usually not associated with disease; this include India, 
Bangladesh, Iran, Australia, Turkey,  Malaysia, Tanzania and South Africa (Parija & 
Khairnar, 2005; Solaymani-Mohammadi et al., 2006; Hooshyar et al., 2012; Fotedar 
et al., 2008; Anuar et al., 2012; Beck et al., 2002; Beck et al., 2008). 
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1.4.2 Extraintestinal amoebiasis  
With regard to ALA, it is commonly present with an acute and sub-acute history of 
fever and right upper quadrant pain, although in 20% to 50% of cases showed a more 
chronic presentation with a protracted history of diarrhoea, weight loss and 
abdominal pain (Ralph & Kempston, 2012). In developed countries, patients who 
present with ALA have usually travelled to one of the endemic regions (Salles et al., 
2003). Knobloch and Manweiler (1983) found that 35% of travellers spent fewer 
than six weeks in an endemic area before developing ALA. A study conducted in the 
province of Thua Thien Hue, in Central Vietnam, reported 2 031 cases of ALA 
between 1990 and 1998, suggesting that the annual incidence of ALA was at least 21 
per 100 000 individuals (Blessman et al., 2002a; Blessman et al., 2002b). The risk of 
acquiring ALA was higher in summer and was age and gender dependent; whereby 
95 % of the cases were adults, and the majority of whom were males (80%). 
Meanwhile, in a retrospective analysis over a 5 year period, in the medical 
emergency of a Northern India Hospital, 86 cases of ALA were reported, with a 
mortality rate of 8.5% (Sharma et al., 2010).  
Based on a 10-year retrospective study from 1998 to 2008, 38 cases of ALA 
were reported in many hospitals in Malaysia (Jamaiah & Shektar, 1999). In a recent 
15 years (from 1999 to 2014) retrospective study, among 6 867 ill returning Israeli 
travelers, 53 were diagnosed with all forms of amoebiasis (0.77%), and the rate of 
ALA among all cases of amoebiasis was 26% (14/53). In addition, twelve of the 14 
cases (86%) had an exposure in the Indian subcontinent (Lachish et al., 2016). 
According to Zeehaida et al. (2008), 58 cases of suspected ALA infection were 
clinically diagnosed at the Hospital Universiti Sains Malaysia (HUSM), with 72.4% 
being seropositive for the presence of anti-E. histolytica antibodies. In another study, 
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approximately 76.7% of the 30 liver abscess cases at HUSM were found positive for 
the presence of E. histolytica DNA in the pus aspirates samples during 2008 and 
2009 (Othman et al.,  2010). ALA was also reported to affect mostly male patients 
between the age of 18 and 50, in whom rates were 3 to 20 times higher between 
populations (De-Bakey & Ochsner, 1951; Abuabara et al., 1982; Katzenstein et al., 
1982; Thompson et al., 1985; Barnes et al., 1987; Acuna-Soto et al., 2000). Other 
than that, ALA was also documented to increase in patients with altered cell-
mediated immunity such as HIV infection, which might increase the likelihood of E. 
histolytica infection causing liver disease (Park et al., 2007). 
 
1.5 Clinical manifestation of amoebiasis 
 
Amoebiasis produces a varied range of clinical manifestations. Hematologic spread 
of E. histolytica infection can lead to intestinal colonization, colitis as well as 
extraintestinal amoebiasis. The disease presentations vary in different populations, 
and depend on factors such as living standard, sanitary condition and nutritional 
status (Petri & Singh, 1999). 
 
1.5.1 Asymptomatic carrier 
The asymptomatic carriers of amoebiasis are individuals with no signs and symptoms 
of either intestinal or extraintestinal amoebiasis, but with the presence of E. 
histolytica trophozoites or cysts in their intestines or stools. Cysts are usually 
detected, though trophozoites with ingested red blood cells are rarely seen. 
Asymptomatic individuals should be treated because they are sources of transmission 
and the disease can develop and progress into an invasive disease. However, often 
there is spontaneous resolution of the infection, without disease development (Haque 
et al., 2001; Blessmann & Tannich, 2002; Blessmann et al., 2006) 
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1.5.2 Intestinal Amoebiasis 
According to Faust et al. (1970), within a year, 4-10% of individuals who are 
asymptomatic may develop the disease. Symptomatic patients usually suffer from 
intestinal amoebiasis and may present as amoebic colitis or amoebic dysentery. 
Typical symptoms of amoebic colitis include gradual onset of abnominal pain (over 
several weeks), tenderness, diarrhoea, fever and bloody stools. The diarrhoea may 
result in 10 or more bowel movements in a day (Reed, 2000). Commonly, multiple 
and small volume mucoid stools are observed, however profuse and watery diarrhoea 
may also be seen (Adams & McLeod, 1977). In addition, bleeding per rectum 
without diarrhoea may be observed, particularly in children (Ralph & Kempston, 
2012). It is surprising that only a small proportion of patients with amoebic colitis 
have fever (8-38%) (Lewis & Antia, 1970; Adams & McLeod, 1977; Abd-Alla & 
Ravdin, 2002).  
However, it is crucial, albeit difficult to distinguish symptoms of infectious 
and non-infectious intestinal diseases. Examples of the latter are inflammatory bowel 
disease, ischemic colitis, diverticulitis, and arteriovenous malformations. These 
could also be confused with bacterial dysenteries that are common in tropical and 
subtropical areas such as shigellosis, campylobacteriosis, salmonellosis, and 
enteropathogenic Escherichia coli infection (Haque et al., 1997; Sakata et al., 2001). 
Moreover, the clinical presentation of amoebic colitis can also be confused with 
Crohn’s disease (Baron, 1996).   
Occasionally, individuals may develop fulminant amoebic colitis, with 
profuse bloody diarrhoea, leucocytosis, fever, and severe abdominal pain, and this 
condition has been reported to result in mortality rate of more than 40% (Stanley, 
2003). Toxic megacolon occurs in approximately 0.5% amoebic colitis cases, and is 
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generally associated with the use of corticosteroids. Since patients with toxic 
megacolon commonly do not respond to anti-amoebic therapy alone, early 
recognition and surgical intervention are important. Ameboma can occur as a result 
of the formation of annular colonic granulation tissue (single or multiple sites) in the 
cecum or ascending colon. In addition, cutaneous amoebiasis (Mhlanga et al., 1992; 
Magaña-Garcia & Arista-Viveros, 1993) and rectovaginal fistulas (Lysy et al., 1991) 
may also be a result of intestinal amoebiasis. Figure 1.3 shows some microscopic 
images of the above.  
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Figure 1.3 Microscopic observations of invasive intestinal amoebiasis, (a) Intestinal flask-shaped ulcers observed through 
rectosigmoidoscopy examination; arrows indicate the colonic ulcers. (b) Large bowel necropsy specimen from a case of fulminant 
amoebic colitis; arrows indicate hemorrhagic ulcers and intestinal mucosa necrosis. (c) Necropsy specimen of liver abscesses; arrows 
indicate the three large abscesses. (d) Intestinal biopsy obtained from the edge of flask-shaped ulcer where large numbers of 
trophozoites (HE and PAS stained, 60x) are clearly visible. (e) Biopsy obtained from the edge of ALA (HE and PAS stained, 20x); 
trophozoites, hepatocytes, and the large number of inflammatory cells are indicated by arrows (Ximenez et al.,2011). 
